Lafadera (Dimethyl Fumarate)

Dimethyl fumarate activates the Nrf2 transcription factor, which up‑regulates antioxidant and cytoprotective genes. This reduces oxidative stress and modulates inflammatory cytokine production, leading to a tempered immune response that is beneficial in autoimmune diseases such as multiple sclerosis and psoriasis.

The dosage of Lafadera is determined by the prescribing clinician based on the individual’s condition, disease severity, and response to therapy. Physicians follow approved labeling and clinical guidelines to titrate the dose, and patients should follow the prescriber’s instructions without self‑adjustment.

Safety of dimethyl fumarate in pregnancy and lactation has not been established. It is classified as pregnancy category unknown, and the drug should only be used if the potential benefit justifies the potential risk to the fetus. Breastfeeding mothers should consult their healthcare provider before use.

To order Lafadera, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements if applicable) and assists with import documentation.

The primary alternative to dimethyl fumarate is another oral disease‑modifying therapy such as fingolimod. While both reduce relapse rates in multiple sclerosis, dimethyl fumarate has a distinct mechanism via Nrf2 activation and a different safety profile, often associated with flushing and gastrointestinal effects, whereas fingolimod carries a higher risk of cardiac events and infections.

Lafadera should be stored at ambient temperature below 25 °C, in its original packaging, protected from moisture and direct sunlight. Keep the product out of reach of children and avoid exposing it to excessive heat or humidity to maintain stability.

Lafadera is taken orally, usually as a tablet swallowed whole with water. The exact administration schedule, including any titration phases, is set by the prescribing clinician and should be followed exactly as instructed.

The most serious risks include significant lymphopenia, which can predispose to opportunistic infections; hepatic injury manifested by elevated liver enzymes; and rare severe hypersensitivity reactions such as anaphylaxis. Patients should report any signs of infection, jaundice, or allergic symptoms promptly.

Lafadera is contraindicated in individuals with severe hepatic impairment, active serious infections, or known hypersensitivity to dimethyl fumarate or any excipients. It should also be used with caution, or avoided, in patients with severe immunosuppression, uncontrolled cardiac disease, or during pregnancy and breastfeeding unless clearly justified.